Clinical trial
LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic…
NCT00295958 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00295958 |
|---|---|
| Title | LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery |
| Official title | Phase II Evaluation of Peptide Immunization and LMB-2 in Metastatic Melanoma |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin), Non-melanomatous Skin Cancer |
| Intervention type | Biological |
| Interventions | LMB-2 immunotoxin, MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant |
| Enrollment | 26 |
| Start date | Dec 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jul 1, 2008 |
| First posted | Feb 24, 2006 |
| Last update posted | Jun 14, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: